Skip to main content
. 2022 Jan 3;22:31. doi: 10.1186/s12885-021-09137-0

Fig. 4.

Fig. 4

The subgroup of patients who had receive perioperative therapy with prior (neo) adjuvant anthracycline- and/or taxane-based regimens, the overall survival in the eribulin and non-eribulin groups (A), early-line eribulin group and non-eribulin group (B) and late-line eribulin group and non-eribulin group (C). OS: Overall survival